Not Yet RecruitingNCT07144072
Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome
PHASE1 · 12 planned enrolment
- Countries listed
- 0
- Registry update
- September 25, 2026
immortal.lifePublic trial registrations naming Hexun Biosciences Co., LTD. as an industry lead sponsor.
This is an independent registry-name view, not a verified corporate profile, portfolio valuation, ownership map, endorsement, or investment recommendation.
This does not mean that no transaction exists. A record appears only after its disclosure source and the connection to this exact registry sponsor identity are separately verified.
PHASE1 · 12 planned enrolment